Zoledronic acid has direct cytotoxic activity on cancer cells, suppresses angiogenesis, inhibits the FGF-2- and VEGF-dependent proliferation of endothelial cells, and inhibits VEGFR-2 in an autocrine cycle [157]. This evidence concerns the gene FGF2 and cancer.